Sentences with phrase «chronic human immunodeficiency virus»

Systemic Cytokine Levels Do Not Predict CD4 (+) T - Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection.

Not exact matches

Relationship between human immunodeficiency virus (HIV - 1) infection and chronic periodontitis — Tábata Larissa — Expert Review of Clinical Immunology

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of thChronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of thchronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Zinc deficiency has been observed in acquired conditions, including malabsorption syndrome (McClain 1985), malnutrition (Keen 1990), cancer (Mocchegiani et al. 1994), alcoholism (Zarski et al. 1987), end - stage liver disease (Pescovitz et al. 1996), uremia (Mahajan et al. 1982) and chronic and acute infectious diseases such as human immunodeficiency virus (HIV) 3 type 1 (HIV - 1) infection (Ripa and Ripa 1995).